The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...